Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antigen-specific regulatory T cells
- Development stage
- Preclinical
- Lead developer
- PolTREG
- Modality
- Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Antigen-specific regulatory T cells (Tregs) are an ex vivo generated cell therapy being developed by PolTREG for the treatment of autoimmune diseases, with a primary focus on Type 1 Diabetes (T1D). Unlike polyclonal Tregs, which represent a broad population of regulatory cells, these antigen-specific Tregs are selected or expanded to recognize specific autoantigens associated with the disease pathology, such as those found in pancreatic islet cells. By targeting specific antigens, these cells are intended to provide localized and potent immunosuppression at the site of inflammation, thereby restoring immune tolerance and preventing the destruction of insulin-producing cells while minimizing systemic side effects. The program is currently in the preclinical development stage.
- Other names
- Ex Vivo Generated Ag-Specific TregsAntigen-specific Tregs (Ex Vivo hodowane agTregs)agTregs
02
Targets
IL-2 (Interleukin 2)NeuraminidaseDisease-specific autoantigen–Major Histocompatibility Complex (pMHC)
Beyond the preview
Go deeper on antigen-specific regulatory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antigen-specific regulatory T cells.